14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $4.61 $7.24 Friday, 3rd May 2024 AFMD stock ended at $5.42. This is 2.26% more than the trading day before Thursday, 2nd May 2024. During the day the stock fluctuated 8.04% from a day low at $5.10 to a day high of $5.51.
90 days $4.25 $7.24
52 weeks $2.24 $11.10

Historical Affimed N.V. prices

Date Open High Low Close Volume
Jan 22, 2021 $65.00 $65.90 $62.33 $65.20 153 504
Jan 21, 2021 $69.80 $70.00 $64.60 $65.80 158 534
Jan 20, 2021 $69.60 $70.50 $66.10 $69.70 209 873
Jan 19, 2021 $70.04 $71.80 $67.20 $69.50 184 138
Jan 15, 2021 $70.70 $70.90 $65.10 $68.80 269 044
Jan 14, 2021 $72.52 $72.52 $68.30 $70.30 265 667
Jan 13, 2021 $66.10 $74.80 $64.90 $72.00 783 403
Jan 12, 2021 $62.50 $67.65 $62.50 $66.20 105 726
Jan 11, 2021 $61.90 $64.40 $60.40 $62.80 115 111
Jan 08, 2021 $64.70 $65.62 $60.10 $61.80 130 597
Jan 07, 2021 $62.20 $64.80 $59.90 $64.40 249 177
Jan 06, 2021 $59.40 $61.40 $57.60 $59.20 124 370
Jan 05, 2021 $60.20 $61.60 $58.90 $59.30 99 605
Jan 04, 2021 $59.50 $62.25 $57.60 $60.60 169 267
Dec 31, 2020 $59.80 $60.10 $57.70 $58.20 82 554
Dec 30, 2020 $59.80 $61.00 $59.30 $59.90 59 467
Dec 29, 2020 $61.00 $62.80 $58.70 $59.30 95 343
Dec 28, 2020 $66.00 $66.15 $59.20 $61.00 228 117
Dec 24, 2020 $64.70 $65.70 $61.50 $64.60 89 900
Dec 23, 2020 $66.10 $66.97 $64.20 $65.15 84 834
Dec 22, 2020 $67.00 $68.15 $65.40 $65.80 97 128
Dec 21, 2020 $63.00 $67.90 $61.10 $66.30 148 619
Dec 18, 2020 $67.90 $68.20 $63.60 $63.60 177 231
Dec 17, 2020 $67.20 $68.00 $64.00 $67.30 88 729
Dec 16, 2020 $69.10 $69.40 $65.50 $66.70 84 570
Click to get the best stock tips daily for free!

About Affimed N.V.

Affimed N.V. Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispec... AFMD Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT